TwinBeech Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

TwinBeech Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-38,352	Closed	-$157K	–	793
2025 Q4	$157K	Buy	+38,352	New	+$190K	0.01%	547
2024 Q4	–	Sell	-535,079	Closed	-$3.53M	–	891
2024 Q3	$3.53M	Buy	535,079 +163,832	+44%	+$1.17M	0.07%	317
2024 Q2	$2.78M	Buy	371,247 +57,760	+18%	+$504K	0.05%	293
2024 Q1	$3.13M	Buy	+313,487	New	+$3.49M	0.06%	282
2022 Q2	–	Sell	-174,923	Closed	-$1.25M	–	704
2022 Q1	$1.25M	Buy	+174,923	New	+$1.86M	0.06%	289

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TwinBeech Capital's RXRX Position: Q1 2026 in Review

TwinBeech Capital sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 38,352 shares — an estimated $157K sold.

TwinBeech Capital first reported a position in RXRX in Q1 2022 and held it in 5 quarters. The position peaked at $3.53M in Q3 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

TwinBeech Capital reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
TwinBeech Capital sold 38,352 Recursion Pharmaceuticals shares in Q1 2026, an estimated $157K.
TwinBeech Capital first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 5 quarters.
TwinBeech Capital's Recursion Pharmaceuticals position peaked at $3.53M in Q3 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.